SCHEMBL8804137

SCHEMBL8804137

c1cc(C2CNCCN2)ccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.39
CHRNB2 P17787 4/20 0.37
CHRNA4 P43681 4/20 0.37
CHRNA7 P36544 3/20 0.37
CYP2C19 P33261 3/20 0.36
MEN1 O00255 2/20 0.36
CYP2D6 P10635 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2A6 P11509 1/20 0.36
CYP2C9 P11712 1/20 0.36
PARP1 P09874 1/20 0.35
ADRB2 P07550 1/20 0.34
NCF1 P14598 1/20 0.34
PLD1 Q13393 1/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
BMPR1B O00238 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL28302986 0.85 CHRNB2 (0.44) RECQLCHRNB2CHRNA4CHRNA7CYP2C19
SCHEMBL12454044 0.83
SCHEMBL9592443 0.79 CHRNB2 (0.62) CHRNB2CHRNA4CHRNA7CYP2C19MEN1
SCHEMBL38661306 0.79 CHRNB2 (0.62) CHRNB2CHRNA4CHRNA7CYP2C19MEN1
SCHEMBL1638075 0.79 SLC18A3 (0.43) MEN1KMT2ACYP2C9BMPR1BPDGFRB
SCHEMBL451612 0.79 SLC18A3 (0.43) MEN1KMT2ACYP2C9BMPR1BPDGFRB
SCHEMBL1639225 0.79 SLC18A3 (0.43) MEN1KMT2ACYP2C9BMPR1BPDGFRB
SCHEMBL8193202 0.78 SLC18A3 (0.47) MEN1KMT2ASMN1; SMN2BMPR1BPDGFRB
SCHEMBL3697306 0.76 PRCP (0.39) BMPR1BPDGFRBKDRACVR1BTGFBR1
SCHEMBL263978 0.76 HTR3A (0.53) CHRNA7PRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
EP-3594297-B1 ORGANIC PHOTOACTIVE LAYER COMPOSITE INK, ORGANIC SOLAR CELL AND PREPARATION METHOD THEREOF SUZHOU INST NANO TECH & NANO BIONICS SINANO CAS (CN) 2025-06-18 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed
US-11895912-B2 Organic photoactive layer composite ink, organic solar cell and preparation methods thereof Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences (CN) 2024-02-06 US disclosed
WO-2022081912-A2 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2022-04-21 WO disclosed
CN-108530977-B Organic photoactive layer composite ink, organic solar cell and preparation method thereof 中国科学院苏州纳米技术与纳米仿生研究所 2021-02-23 CN disclosed
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 US disclosed
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 US disclosed
US-5659038-A GRAMPOSITIVE/GRAMNEGATIVE MICROBIOCIDES; ANTISEPTICS, HUMAN AND VETERINARY MEDICINE BAYER AKTIENGESELLSCHAFT (DE) 1997-08-19 US disclosed
EP-0523512-B1 8-vinyl- and 8-ethinyl-quinolone carboxylic acids BAYER AG (DE) 1997-01-15 EP disclosed
US-5578604-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1996-11-26 US disclosed
US-5468742-A Antibacterial agents, feed additives BAYER AKTIENGESELLSCHAFT (DE) 1995-11-21 US disclosed
CN-1111629-A 5-vinyl-, 5-ethynylquinolone-and 5-vinyl-, 5-ethynylnaphthyridonecarboxylic acids BAYER AG (DE) 1995-11-15 CN disclosed
EP-0671391-A1 5-Vinyl- and 5-ethinyl-quinolinone- and -naphthyridone-carboxylic acids BAYER AG (DE) 1995-09-13 EP disclosed
US-5210193-A Bactericide AMERICAN CYANAMID COMPANY (US) 1993-05-11 US disclosed
EP-0523512-A1 8-vinyl- and 8-ethinyl-quinolone carboxylic acids BAYER AG (DE) 1993-01-20 EP disclosed
WO-1991019707-A2 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1991-12-26 WO disclosed
US-4940710-A 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids AMERICAN CYANAMID COMPANY (US) 1990-07-10 US disclosed
EP-0230053-A2 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids AMERICAN CYANAMID COMPANY (US) 1987-07-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076924-A1 Piperazines as P2X7 antagonists P2RX7, P2RX1, P2RX2 RECQL 1709/4885CHRNB2 573/4885CHRNA4 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.